Dr. Lal Pathlabs Ltd. (LALPATHLAB) Share Price Hits 52-Week High
- August 4, 2026
- Posted by: Harsh Piplani
- Category: News
Dr. Lal Pathlabs Ltd. Share Price reached a 52-week high of Rs 1,950.45, up 1.65% today, with a market cap of Rs 31,976.9 crore.
Dr. Lal Pathlabs Ltd. Share Price has reached a new 52-week high of Rs 1,950.45, marking a significant milestone for the company. The stock closed at Rs 1,926.4, reflecting a 1.65% increase from the previous close of Rs 1,895.1. With a market capitalisation of Rs 31,976.9 crore, Dr. Lal Pathlabs Ltd. continues to capture investor attention in the healthcare sector. This achievement underscores the company’s strong market position and investor confidence, although the data does not specify a particular catalyst for today’s rise.
Dr. Lal Pathlabs Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,926.4 |
| Previous Close | Rs 1,895.1 |
| Today's Change | +Rs 31.3 (+1.65%) |
| Day Open | Rs 1,932.7 |
| Fresh 52-Week High | Rs 1,950.45 |
| Day Low | Rs 1,910 |
| Current Volume | 5,739 |
| Turnover | Rs 1.11 crore |
| Market Capitalisation | Rs 31,976.9 crore |
Dr. Lal Pathlabs Ltd. (LALPATHLAB) traded at Rs 1,926.4. versus the previous close of Rs 1,895.1, a rise of 1.65%. The stock opened at Rs 1,932.7, reached Rs 1,950.45, touched Rs 1,910. Reported volume was 5,739.
Today, Dr. Lal Pathlabs Ltd. opened at Rs 1,932.7 and reached a high of Rs 1,950.45, setting a new 52-week peak. The stock’s low for the day was Rs 1,910, with a turnover of Rs 1.11 crore. The current volume of 5,739 shares indicates moderate trading activity. The 1.65% increase from the previous close highlights positive investor sentiment. This price action sets the stage for further analysis of the company’s fundamentals and sector context.
Dr. Lal Pathlabs Ltd. (LALPATHLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 31,976.9 crore |
| P/E Ratio | 39.39x |
| P/B Ratio | 7.98x |
| ROE | 28.21% |
| ROCE | 26.35% |
Dr. Lal Pathlabs Ltd. was valued at a P/E ratio of 39.39x, a P/B ratio of 7.98x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of 28.21% and ROCE of 26.35%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 39.39x |
| Benchmark Median P/E | 20.89x |
| Benchmark Average P/E | 73.74x |
| Benchmark P/E Range | 0x to 3,364.06x |
| Company P/B Ratio | 7.98x |
| Benchmark Median P/B | 1.9x |
| Company ROE | 28.21% |
| Benchmark Median ROE | 10.92% |
| Company ROCE | 26.35% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 31,976.9 crore |
| Benchmark Median Market Cap | Rs 139.24 crore |
Dr. Lal Pathlabs Ltd. (LALPATHLAB) is classified under sector: Healthcare.
Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 39.39x, which is above the benchmark median of 20.89x, a difference of +88.56%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROE of 28.21%, which is above the benchmark median of 10.92%, a difference of +158.33%. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a ROCE of 26.35%, which is above the benchmark median of 13.29%, a difference of +98.27%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd. | KPL | 2,683.28 | 39.39 | 7.98 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,474.26 | 62.88 | 9.95 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,421.1 | 34.54 | 6.99 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,416.82 | 171.93 | 3.18 | 13.9 | 12.97 |
| Hester Biosciences Ltd. | HESTERBIO | 2,111.45 | 15.25 | 4.57 | 16.17 | 14.12 |
Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a P/E ratio of 39.39x compared with the displayed peer median of 39.39x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 28.21% compares with a peer median of 16.17% across the companies shown in the table. ROCE stood at 26.35% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Dr. Lal Pathlabs Ltd. (LALPATHLAB) has a market capitalisation of Rs 31,976.9 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Dr. Lal Pathlabs Ltd.
- Achieved a fresh 52-week high of Rs 1,950.45.
- Strong fundamentals with high ROE and ROCE.
- Leading market cap in the healthcare sector.
- Valuation metrics above sector medians.
About Dr. Lal Pathlabs Ltd.
Dr. Lal Pathlabs Ltd. is a prominent player in the healthcare sector, offering a wide range of diagnostic and related healthcare tests. The company operates a network of laboratories and patient service centers across India, providing services to individual patients, hospitals, and other healthcare providers. Its comprehensive test menu includes routine and specialized tests, catering to a diverse clientele. Dr. Lal Pathlabs Ltd. is known for its quality services and technological advancements, maintaining a strong market presence.
Track Dr. Lal Pathlabs Ltd. Share Price on Univest
Use Dr. Lal Pathlabs Ltd. (LALPATHLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Dr. Lal Pathlabs Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed with real-time data and comprehensive analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Dr. Lal Pathlabs Ltd.?
Ans. The current share price of Dr. Lal Pathlabs Ltd. is Rs 1,926.4, marking a 1.65% increase from the previous close of Rs 1,895.1. The stock moved 1.65% during the session.
What is the 52-week high of Dr. Lal Pathlabs Ltd.?
Ans. Dr. Lal Pathlabs Ltd. reached a 52-week high of Rs 1,950.45 today, reflecting strong market performance. The stock moved 1.65% during the session. The intraday range extended from Rs 1,910 to Rs 1,950.45.
How does Dr. Lal Pathlabs Ltd.'s P/E ratio compare to the sector?
Ans. Dr. Lal Pathlabs Ltd.'s P/E ratio of 39.39 is higher than the healthcare sector median of 20.89, indicating a premium valuation. The company trades at a P/E ratio of 39.39x.
What is the market capitalisation of Dr. Lal Pathlabs Ltd.?
Ans. Dr. Lal Pathlabs Ltd. has a market capitalisation of Rs 31,976.9 crore, positioning it as a major player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 39.39x.
How does Dr. Lal Pathlabs Ltd.'s ROE compare to its peers?
Ans. Dr. Lal Pathlabs Ltd.'s ROE of 28.21% is higher than many of its peers, showcasing strong profitability and efficient capital use. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.
What is the P/B ratio of Dr. Lal Pathlabs Ltd.?
Ans. The P/B ratio of Dr. Lal Pathlabs Ltd. is 7.98, which is above the sector median of 1.9, indicating a higher valuation. The company trades at a P/E ratio of 39.39x.
Who are the peers of Dr. Lal Pathlabs Ltd.?
Ans. Peers of Dr. Lal Pathlabs Ltd. include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., and Dr Agarwals Eye Hospital Ltd., among others. Comparable listed companies include Kwality Pharmaceuticals Ltd., Beta Drugs Ltd., Dr Agarwals Eye Hospital Ltd.
How does Dr. Lal Pathlabs Ltd.'s ROCE compare to the sector?
Ans. Dr. Lal Pathlabs Ltd.'s ROCE of 26.35% is significantly higher than the sector median of 13.29%, indicating efficient capital use. ROE stands at 28.21%. ROCE stands at 26.35%. The relevant peer median ROE is 10.92%.
